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BACKGROUND: Hypermethylation of RASSF1A and CDKN2A is one of epigenetic factor underlies nasopharyngeal carcinoma (NPC) development. 
Smoking behavior as an NPC’s risk factor causes aberrant 
DNA methylation. RASSF1A and CDKN2A promoter 
hypermethylation from peripheral blood cells correlates 
with smoking behavior. The use of body fluids including 
peripheral blood as a specimen for DNA methylation 
analyzes are widely developed, as less invasive method 
compared to the use of tissue biopsy.  This study aims to 
observe the association between RASSF1A and CDKN2A 
methylation in peripheral blood and smoking behavior 
among NPC patients.
METHODS: Newly diagnosed NPC subjects were 
recruited from ear-nose-throat (ENT) outpatient clinic of 
Dr. Sardjito Hospital, Yogyakarta. DNA from buffycoat 
of 19 smokers and 20 non-smokers NPC’s patients were 
isolated. Bisulphite modification was applied to 500 ng 
of the isolated DNA. The methylation status was detected 
by MSP (methylation-specific polymerase chain reaction 
(PCR)). The association between smoking status and 
promoter hypermethylation was analysis using Chi-Square 
test.
RESULTS: MSP analysis of RASSF1A showed that 
68.42% smoker and 75% non-smoker NPC’s patients 
were methylated. MSP analysis of CDKN2A showed that 
21.05% smoker and 25% non-smoker NPC’s patients were 
methylated. There was no association between smoking 
behavior with RASSF1A and CDKN2A methylation 
(p>0.05).
CONCLUSION: Statistical analysis showed that smoking 
behavior is not associated with methylation of RASSF1A 
and CDKN2A among NPC’s patients. 
KEywORDS:  DNA methylation, CDKN2A, RASSF1A, 
Nasopharyngeal carcinoma, Smoking
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Abstract
Introduction
Nasopharyngeal carcinoma (NPC) is a rare malignancy 
worldwide,  with  incidence  of  less  than  1/100.000 
populations.(1) However,  in  some  regions,  including 
South-east  Asia, the incidence is high. The incidence 
of NPC in Indonesia is predicted as high as 5-7/100.000 
populations.(2) Late clinical presentation and bad prognosis 
are characteristic of NPC.(3,4) Cigarette smoking is common 
risk of cancer, including nasopharyngeal carcinoma. 
Carcinogenic materials in cigarette such as arsenic, 
chromium, formaldehyde, polycrilic acromatic hydrocarbons 
and nitrosamines causes DNA damage. Cigarette smoke 
is considered one of the most powerful environmental 
modifiers of DNA methylation. The specific mechanisms 
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of how cigarette smoke may alter DNA methylation are 
becoming better understood.(5) Cigarette smoking causes 
DNA damage, hypoxia, activated DNA-binding protein and 
accumulation  of  DNA  methyltransferase.  This  condition 
can cause an alteration of DNA methylation.
 Hypermethylation DNA is the most studied epigenetic 
alteration in cancer. It has been described for variety of cancer 
including NPC. Hypermetilation DNA of promoter tumor 
suppressor gene causes expression silences from the gene. 
These genes are very important for controlling proliferation, 
cell cycle, cell motility and apoptosis. Aberration of DNA 
methylation mostly caused by environmental factors.(6,7)
RASSF1A and CDKN2A genes are tumor supressor genes 
that involved in NPC pathogenesis. Several studies were 
demonstrated that both genes has been methylated in NPC.
(8–10) Cigarette smoking was associated with RASSF1A and 
CDKN2A methylation status among lung cancer patients.
(11) However, there has been no study that correlates 
smoking behavior and RASSF1A and CDKN2A methylation 
status in NPC.
 Methylation study in NPC using leukocytes has never 
been done. However, there was a study in RASSF1A and 
CDKN2A methylation using leukocytes. This study was 
consist of smoker and non-smoker groups and the results 
showed that RASFF1A and p16 (CDKN2A) methylation 
were higher in smokers than non-smokers group.(20) 
 The use of body fluids including peripheral blood 
as a specimen for DNA methylation analyzes are widely 
developed. That specimens were obtained less invasively 
compared to tissue biopsy, and might be resampled more 
frequently. Detection of DNA methylation in peripheral 
blood have been reported in several studies, including lung 
cancer (12), pancraetic cancer (13) and ovarium cancer 
(14). This study reports the observation of RASSF1A 
and CDKN2A methylation in peripheral blood, and their 
association with smoking behavior among NPC patients.
Methods
This study used newly diagnosed NPC subjects were 
recruited from ear-nose-throat (ENT) outpatient clinic 
Dr. Sardjito General Hospital, Yogyakarta, as part of 
NPC Hospital-based case-control study (2012-2016; 
Principle investigator: Jajah Fachiroh). Smoking status was 
determined through questionnaire. Smokers are those who 
smoke regularly for at least a year, while non-smokers are 
those who never smoke regularly for at least one year in their 
life. Ethical permission was given by Faculty of Medicine 
UGM Internal review board number KE/FK/730/EC, and 
informed consent was given prior to data collection. 
 We selected 19 NPC who smoked and 20 NPC who 
did not smoke to enter this study. All subjects were male 
and Javanish. DNA from buffycoat of peripheral blood was 
extracted by using Geneaid DNA Isolation Kit (Geneaid 
Biotech. Ltd, Taiwan). Five-hundred ng of DNA was used 
for bisulfite treatment using commercially kit Cells-to-CpG 
Bisulfite Modification (Applied Biosystem, Massachusetts, 
USA). 
 MSP (Methylation-specific polymerase chain reaction 
(PCR)) was used as methylation analysis. The PCR specific 
primer consist of methylation and unmethylation sequences. 
This four pairs of specific primer was obtained from 
previous study.(15,16) Modified DNA from breast tissue 
which known RASSF1A and CDKN2A metylation status 
was used as positive control. Distilled water was used for 
negative control. Platinum® Taq Polymerase (Invitrogen, 
Massachusetts, USA) was used for amplification. Fluorosafe 
DNA stain (1st Base, Singapore) was used for nucleic acid 
stain. Electroforesis’s product was visualized using UV 
translumination.
 Association between smoker and non-smoker NPC’s 
patients was analysis using Chi-Square. Two sided p≤0.05 
was considered as statistically significant. All statistical 
calculations was performed using SPSS ver. 23 (SPSS Inc., 
Chicago, USA).
Results
Subjects characteristic were divided based in their 
smoking status (Figure 1). Analysis showed that there 
were no differences in age group and histopathological 
characteristics. Median age group and years of smoking 
was grouped on the median value in smoker NPC’s patients 
and non-smoker NPC’s patients. WHO histopathological 
type in both groups was not significantly different. Smoking 
duration ranged from 8-61 years with median of years 32. 
Number of cigarette smoked was ranged from 2-36 cigarettes 
per day with median 10 cigarette per day (Table 1). 
  A   1     2    K(+)   L     1     2   K(+)       B    1       2     K(+)            1     2   K(+) 
Figure 1. MSP result for RASSF1A (A) and CDKN2A (B) 
methylation detection. (A) Sample 1 is a methylation sample and 
sample 2 is an unmethylation sample. (B) Sample 1 is a methylation 
sample and sample 2 is an unmethylation sample.
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Case (%)
n = 19
Control (%)
n = 20 p *
Mean (±SD) 50.90 (±10.21) 51.15 (±11.18)
Median 51.5 53.5
Range 33-76 25-66
Type 1 0 (0) 0 (0)
Type 2 0 (0) 1 (5)
Type 3 19 (100) 19 (95)
< 32 9 (47.4)
≥ 32 10 (52.6)
Range 8-61
< 10 6 (31,6)
≥ 10 13 (68.4)
Range 2-36
Age (years)
WHO Type
Smoking duration (years)
Cigarette per day
0.444
1000
Subject Characteristics
Table 1. Subject Characteristics. There were no significance 
differences in age group between smoker and non-smoker NPC’s 
patients. There were no significant differences in WHO type of 
cancer between smokers and non-smokers subjects.
 DNA methylation analysis used MSP. MSP 
methylation products of RASSF1A is 94 bp meanwhile 
unmethylation products is 105 bp. Methylation products of 
CDKN2A is 150 bp and unmethylation products is 151 bp 
(Figure 1). Meanwhile the primer specific for MSP in both 
genes are shown in Table 2. 
 MSP analysis of RASSF1A showed that 68.42% smoker 
and 75% non-smoker NPC’s patients were methylated. MSP 
Discussion
Aberrant cell growth is commonly reported as result of DNA 
mutation. However, compared to other type of cancers, 
methylation is more often reported to occur in NPC.(7) 
Gene methylation occurs in the tissue of nasopharynx or 
Epstein-Barr virus (EBV) gene to support its oncogenic 
role.(4) Several studies reported the occurrence of promoter 
methylation in tumor suppressor genes in NPC.(8-10) All of 
these studies used tissue from the nasopharynx as reflecting 
in situ epigenetic changes. 
 However, the use of nasopharynx tissue has been 
limited by its quantity and quality. Nasopharyngeal 
carcinoma is not an operable cancer, biopsy yielding small 
cut  of  tissue, that  used  mostly  for  histopathological 
diagnosis preparation (formalin-fixed paraffin embedded 
(FFPE)), biopsy is an invasive method, operated only by 
clinical specialist; thus, limit  the  frequent  use.  The  use 
of  nasopharyngeal  brush which targets the exfoliating 
epithelial cells was also suggested.(8) This technique 
Gene Primer Sequences Product
F: 5’-GTGTTAACGCGTTGCGTATC-3’
R: 5’-AACCCCGCGAACTAAAAACGA-3’
F: 5’-TTTGGTTGGAGTGTGTTAATGTG-3’
R: 5’-CAAACCCCACAAACTAAAAACAA-3’
F: 5’-TTATTAGAGGGTGGGGCGGATCGC-3’
R: 5’-GACCCCGAACCGCGACCGTAA-3’
F: 5’-TTATTAGAGGGTGGGGTGGATTGT-3’
R: 5’-CAACCCCAAACCACAACCATAA-3’
CDKN2A Methylation 150 bp
Unmethylation 151 bp
RASSF1A Methylation 94 bp
Unmethylation 105 bp
Table 2. Primer specific for MSP in both genes.
Methylation % Unmethylation % p*
Smoker 13 68.42 6 31.58
Non-smoker 15 75 5 25
CDKN2A Smoker 4 21.05 15 78.95
Non-smoker 5 25 15 75
RASSF1A 0.731
1
Table 3. The association between smoking behaviour and RASSF1A and CDKN2A methylation. 
analysis of CDKN2A have a similar result. It showed that 
21.05% smoker and 25% non-smoker NPC’s patients were 
methylated (Table 3).
 Smoking behaviour of NPC’s patients was not 
significantly associated with RASSF1A and CDKN2A 
methylation. This results was proved using Chi-Square test 
with p value>0.05 (Table 3). 
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required ENT specialist to handle guided endoscopy to 
target the sampling area.
 The use of peripheral blood is considered as a better 
replacement for less invasiveness and capacity for more 
frequent  sampling,  therefore  suitable  to  be  used  for 
screening or follow up. Cell-free DNA (cfDNA) has recently 
being used to replace tissue, with the assumption that DNA 
was originated from cancer tissues (6) as the result of 
apoptosis. However, the efficiency of cfDNA is quite low. 
On the other hand, the use of whole blood/ blood cells is also 
an option. Immunologic process related to inflammation in 
cancer development has been suggested to lead the changes 
in the leucocyte  populations. That  changes could  alter 
epigenetic in peripheral blood.(17) Development of DNA 
methylation study in peripheral blood is expected can 
describe tissue’s methylation condition. The methylation 
study in brain tissue, breast cancer and colorectal cancer 
showed that peripheral blood’s methylation couldn’t 
describe condition in tissues.(18,19) However, the study 
in lung tissue showed different result.(12) Within limited 
sample we could demonstrate parallel detection of RASF1A 
in FFPE tissue of nasopharynx and blood cells (data not 
shown). 
 Tobacco smoking has been reported to cause 
epigenetic changes, as reported by Huang, et al.(11) Within 
this study, we found no association between smoking 
behavior and RASSF1A and CDKN2A methylation in NPC’s 
patients.  In both smokers and non-smokers we found 
similar distribution of RASSF1A and CDKN2A methylation. 
Previous study using FFPE of the nasopharynx and exfoliate 
of nasopharynx tissue showed that that RASSF1A and 
CDKN2A methylation status in NPC’s patients were higher 
than non-cancer patients.(8,10) Study done by Deep, et 
al.,showed that methylation in both genes were high among 
smokers compared to non-smokers.(12,20) Which shed light 
for the possibility to use these process as biomarkers for 
smoking. In our hand, we could not confirm the difference 
of smoking behavior, instead to confirm parallel results of 
RASSF1A and CDKN2A methylations in NPC. This study 
has limitation, including the absence of passive smoking 
status, and limitation of sample numbers.
Conclusion
As a conclusion, within this study we were able to detect 
DNA methylation of RASSF1A and CDKN2A in the cells 
of the peripheral blood. DNA methylation of RASSF1A 
and CDKN2A in peripheral blood were not associated with 
smoking behavior among NPC subjects. Further, analysis 
by using healthy blood donor may help us to conclude the 
status of methylation of RASSF1A and CDKN2A, either as 
marker for smoking or for cancer. 
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